Other languages Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
15.68 ^USD	-2.00%		+1.49%	-40.11%

04-25	Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
04-25	Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	03-21
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	03-21
Top Premarket Decliners	03-21
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	03-19
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	03-19
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	01-31
Tourmaline Bio Prices $150 Million Common Stock Offering	01-25
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	12-14
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	11-30
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing	23-10-27
Tourmaline Bio Insider Bought Shares Worth $110,912, According to a Recent SEC Filing	23-10-26
Tourmaline Bio Completes Merger With Talaris Therapeutics	23-10-19
Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	23-10-18
Talaris Therapeutics Shareholders OK Merger With Tourmaline Bio	23-10-18
MORNING BRIEFING - USA/Asien	23-10-09
Talaris Therapeutics, Inc. Announces Special Dividend	23-10-06
Talaris Therapeutics Sells Tolerance Business to ImmunoFree	23-08-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Other languages

Filters